ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
The expression and clinical significance of high mobility group nucleosome binding domain 5 in human osteosarcoma.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Chromatin structural gene expression stratifies cardiac cell populations in health and disease.Epigenetics · 2025Article
- Exogenous HMGN2 inhibits the migration and invasion of osteosarcoma cell lines.Translational cancer research · 2020Article
- HMGN5 Silencing Suppresses Cell Biological Progression via AKT/MAPK Pathway in Human Glioblastoma Cells.BioMed research international · 2020Article
- The nucleosome binding protein 1 promotes the growth of gastric cancer cells.Journal of Cancer · 2019Article
- Hypoxia-Inducible Factor 1A Upregulates HMGN5 by Increasing the Expression of GATA1 and Plays a Role in Osteosarcoma Metastasis.BioMed research international · 2019Article
- Transcriptional Profiling of Host Cell Responses to VirulentInternational journal of molecular sciences · 2018Article
- miR-488 inhibits cell growth and metastasis in renal cell carcinoma by targeting HMGN5.OncoTargets and therapy · 2018Article
- Knockdown of HMGN5 increases the chemosensitivity of human urothelial bladder cancer cells to cisplatin by targeting PI3K/Akt signaling.Oncology letters · 2017Article
- MicroRNA-409-3p Represses Glioma Cell Invasion and Proliferation by Targeting High-Mobility Group Nucleosome-Binding Domain 5.Oncology research · 2017Article
- MicroRNA-140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy.Scientific reports · 2017Article
- Hmgn5 functions downstream of Hoxa10 to regulate uterine decidualization in mice.Cell cycle (Georgetown, Tex.) · 2016Article
- Research advances in HMGN5 and cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Shikonin inhibits invasiveness of osteosarcoma through MMP13 suppression.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5637 cells in vitro and in vivo.Medical oncology (Northwood, London, England) · 2015Article
- The high-mobility group nucleosome-binding domain 5 is highly expressed in breast cancer and promotes the proliferation and invasion of breast cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The high mobility group nucleosome binding domain 5 (HMGN5) is a member of the high mobility group proteins family and highly expressed in multiple malignancies. Nevertheless, the role of HMGN5 in osteosarcoma remains unclear. This study aimed to investigate the expression and clinical significance of HMGN5 in human osteosarcoma, confirm the oncogenic role of HMGN5 and explore the mechanism by which HMGN5 contributes to invasion and metastasis. HMGN5 expression was detected in osteosarcoma tissues and corresponding adjacent non-cancerous tissues (ANCTs) from 52 patients by immunohistochemical (IHC) assay and the clinicopathologic characteristics of all patients were also recorded. Next, osteosarcoma cells were transfected by HMGN5 RNA interference and cell viability, apoptosis and invasion were detected by cell vitality test, flow cytometry and transwell assay, respectively. As a result, IHC assay showed strong immunized activity of HMGN5 in the nucleus in all osteosarcoma tissues compared with the ANCT (53.5 ± 4.3 % vs. 17.0 ± 3.9 %, P < 0.01). HMGN5 expression level was associated with pathologic staging and TNM staging. Knockdown of HMGN5 induced cell cycle arrest, inhibited invasion and increased sensitivity to doxorubicin-induced cell apoptosis in U2-OS and SaO2 cells. Western blot analysis demonstrated that there were increased expressions of cleaved caspase-3, cleaved PARP and decreased expressions of PCNA, PI3Kp85α, p-AKT, MMP-9, and cyclin B1 in U2-OS and SaO2 cells depleted of HMGN5. HMGN5 plays oncogenic role in osteosarcoma by promoting cell proliferation and invasion, and could be exploited as a target for therapy in osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.